Gulden introduces Aurosling for surgical correction of ptosis

Article

New device for surgical correction of ptosis.

Elkins Park, PA-Gulden Ophthalmics introduces Aurosling, the frontalis suspension sling used in the surgical procedure for the correction of ptosis. The frontalis sling procedure, the most common surgery for ptosis, uses the frontalis muscle of the forehead to help lift the eyelid by placing a sling of material between the forehead and the eyelid.

Aurosling is a sterile implantable flexible silicone rod with a silicone sleeve attached to two malleable sharp straight needles. Silicone, unlike other materials, is not associated with frequent recurrence of ptosis and is often used as a permanent solution. The material can be adjusted, both intraoperatively and post-operatively, if the eyelid height needs to be altered over time.

The 40 cm, flexible silicone rod helps in good lid closure and provides excellent bio-compatibility. The 7 mm-long sleeve helps in easy adjustments and facilitates easy implantation. Needle length is 6.3cm, diameter is 920 micron.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.